Inivata and Gustave Roussy Presented Data at World Lung Conference Demonstrating the Clinical Use of Liquid Biopsy Approaches in Lung Cancer Patients when Tissue is Not Available
Inivata and Gustave Roussy Presented Data at World Lung Conference Demonstrating the Clinical Use of Liquid Biopsy Approaches in Lung Cancer patients when Tissue is Not Available
Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, presented data with collaborators from Gustave Roussy at the 17th World Conference on Lung Cancer in Vienna. The data generated in the joint project explores the clinical benefit for non-small cell lung cancer (NSCLC) patients treated with osimertinib who were EGFR T790M-positive based on a novel, blood-based liquid biopsy test, InVision™. The researchers looked at response rates specifically in advanced patients with resistance to at least one prior EGFR targeted therapy who were not able to have a tissue biopsy. They found that of the 48 patients tested, 24 patients (50%) were EGFR T790M-positive. Of the 24 positive patients, 9 patients had an allele fraction lower than 0.5%, at frequencies that may be missed using less sensitive assays. For the patients who were treated with osimertinib and evaluable for treatment response, the objective response rate was 62.5% with the remaining patients having stable disease as their best overall response. The study supports the use of liquid biopsies as a surrogate marker for T790M in tumor tissue, avoiding the need for invasive tumor biopsies for personalizing treatment in lung cancer patients.
On December 7, Inivata presented analytical performance data for InVision comparing results from both their Cambridge, UK laboratory as well as their U.S. CLIA certified laboratory. The data showed high concordance across both laboratories including strong correlation of InVision ctDNA results compared to a digital PCR-based approach.
Clive Morris, Chief Medical Officer at Inivata, said:
“We are impressed with the performance of our InVision platform across a variety of clinical scenarios in terms of robustness, reproducibility, and actionability. The results are encouraging as we continue to generate further data to support clinical use of our InVision platform.”
Details of the posters presented are provided below:
Abstract ID: #6389
Title: Validation and Performance of a Standardized ctDNA NGS Assay across Two Laboratories,
Abstract ID: #5472
Title: Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.